Ranking your own book by conviction, the two adjusted-profit metrics that make serial acquirers legible (FCFA2S and NPATA), buying a private-equity book at a discount to its stated value, and what to do when a founder is margin-called.
1. Rank your own holdings into conviction tiers, and write the reason for the tier
The repeatable method
- Periodically stop screening for new ideas and instead rank what you already own, from most to least sure. Four bands is enough: favourites · no doubts · proud owner but real risks · should this be sold.
- For every name, answer two questions in writing — how does it make money, and why is the conviction at this tier rather than one higher.
- Force the second answer to name a single specific reason. A tier demotion with no nameable cause means the ranking is a feeling, not an analysis.
- Treat the bottom tier as an explicit sell queue, reviewed on a schedule rather than when the price moves.
Here: 18 holdings across Very Strong / Strong+ / Strong / Medium, with each demotion attributed to one thing — BRO to a single oversized acquisition, KPG.AX to the founder's behaviour. MEDP shows the inverse: full price ("Forward PE of 30.3x") does not demote a name, because valuation is not what the tiers measure.
Watch for
- Tier inflation — if nothing ever sits in the bottom band, the ranking has stopped doing work.
- A demotion reason that quietly becomes a thesis break; the tier should move to a sale, not stay parked, once the cause is confirmed.
2. For a serial acquirer, value the cash available to owners — not reported earnings
The repeatable method
- Identify the accounting distortion first: an acquisitive company must amortise the purchase price of what it buys, which suppresses reported profit without any cash leaving the business.
- Rebuild the owner's number instead. For a software roll-up that is Free Cash Flow Available To Shareholders (FCFA2S) — free cash flow after the claims of minorities and debt-holders.
- Apply an explicit, stated growth assumption for the coming year rather than a multi-year model, and say what it is so a reader can disagree with one input.
- Express the result as a forward yield on that cash and compare it with the company's own history, not with a sector average.
Here: CSU.TO — FCFA2S of $1,683m USD in 2025, +15% assumed, gives a 4.8% forward yield: "the cheapest valuation level the company has ever traded at." TOI.V — €218.7m, +20% assumed, gives 5.1%. Same metric, same sentence, two companies.
Watch for
- The growth assumption doing all the work — at +0% instead of +15%, the yield and the "cheapest ever" claim both change materially.
- Whether the acquisition pipeline still absorbs the cash at good returns; the whole model depends on redeployment, not on the yield itself.
3. Use NPATA (or any owner-earnings adjustment) where amortisation is not a real cost — and build the multi-year ladder
The repeatable method
- Where a business acquires intangible assets — client lists, customer relationships, books of business — add back the amortisation of those intangibles to get the cash profit an owner actually receives. Kelly Partners' name for it is NPATA; Buffett's is Owner Earnings.
- Apply the current price to that figure for a forward multiple.
- Then lay management's own multi-year targets against today's price to produce a ladder of multiples, so the question becomes "do I believe the plan?" instead of "is the multiple high?"
- Keep the targets as management's, explicitly attributed — the ladder is a test of credibility, not a forecast you have made.
Here: KPG.AX — $11m NPATA in 2026 = 20.8x forward, "not expensive given the long runrate," with management's $16m / $20m / $25m targets for 2027-29 converting today's price to 14.3x / 11.5x / 9.2x.
Watch for
- Add-backs that are real costs — if the acquired client relationships genuinely run off and must be replaced with new acquisitions, the amortisation is a maintenance expense in disguise.
- The first missed rung on the ladder; a serial acquirer's forward targets assume deals that have not yet been done.
4. Treat a founder's pledged shares as a governance red flag — and re-underwrite the person, not the price
The repeatable method
- Check whether insiders have pledged shares as collateral for personal borrowing. Skin in the game financed with debt is not skin in the game.
- Model the reflexive loop: a falling price triggers a margin call, forced selling pushes the price lower, which triggers more calls. The founder becomes a forced seller precisely when the company most needs a stable register.
- Separate the two questions the event raises — has the business deteriorated (usually no), and has your read on the operator's judgement changed (possibly yes).
- Respond by contacting management and setting a date to conclude, rather than by trading the headline in either direction.
- Cap the position's conviction tier until the question is closed, and say out loud what would resolve it.
Here: KPG.AX — the AFR (2026-04-13) reported Brett Kelly margin-called on $64m of pledged shares, with 7m+ shares (34% of his stake) moved into holding accounts before the fall and ultimately handed to an undisclosed lender, "which put a lot of pressure on the stock price." Slegers: "This is not good governance if you ask me. It's something Warren Buffett would never ever do… I'm having a call with Brett Kelly next Monday and will see him in Omaha again later this month."
Watch for
- Whether remaining pledges are disclosed and unwound — one margin call rarely exhausts the borrowing.
- The distinction between an owner-operator and a promoter, which usually shows up in guidance quality rather than in one event.
5. Judge a serial acquirer on deal cadence, not just deal price
The repeatable method
- Establish the acquirer's normal deal size relative to its own market value; that cadence is the model you underwrote.
- When a transaction is an order of magnitude larger, treat it as a change in the risk profile even if the price looks defensible — many small bets average out, one large bet does not.
- Do the dilution arithmetic explicitly: capital raised, resulting share-count increase, and the incremental profit at the acquirer's own margins, so you can see whether the deal pays for its own dilution.
- Then decide whether it changes the conviction tier rather than the ownership.
Here: BRO's $9.83bn Accession purchase — $4bn raised, 13.3% dilution, 5.7x revenue paid against a 6.2x earnings multiple, ~$148m of added net income at BRO margins (+13.6%). "We prefer Serial Acquirers to execute a lot of small acquisitions" — enough to keep it out of the top tier, not enough to sell.
Watch for
- Integration evidence over the following two to four quarters — whether the acquirer's margins actually get applied to the acquired revenue.
- Organic growth being masked by the acquisition once the two are combined in the reported line.
6. Buy a listed vehicle at a discount to a published asset value — and check the assets first
The repeatable method
- For a trust, holding company or asset manager that publishes a net asset value, analyse the underlying holdings before the wrapper: growth, margins, and whether the assets are the kind that hold their marks.
- Compare the share price with the published NAV per share and express the gap as a discount.
- Compare that discount with the vehicle's own history — a wide discount is only an opportunity relative to where it normally trades.
- Recognise the two ways you get paid: NAV compounding, and the discount narrowing.
Here: HGT.L — underlying sales +17%, EBITDA +19% at a 33% margin, against an NAV of £5.62 and a discount "of almost 30%… very high from an historical perspective." BN runs the same logic on management's own intrinsic-value estimate: $68 against a $46.5 price, a 30% discount "very large from a historical perspective."
Watch for
- How the NAV is struck — private holdings are marked by their owner, so the discount is only as real as the marks.
- A discount that never closes; without buybacks, realisations or a catalyst, you are relying entirely on the assets compounding.
7. Value the same company two independent ways and require both to agree
The repeatable method
- Pick two measures that fail differently — an asset-based one (NAV, sum of the parts) and an earnings-based one (a multiple of the cash profit).
- Run both at today's price and state each result as a single number.
- Act only when both say the same thing; a disagreement is information about which measure is wrong, and the work is not finished.
- For the earnings leg, show today's multiple and the multiple on management's out-year guidance, so the implied bet is visible.
Here: BN — a 30% discount to a $68 intrinsic value on one side, and Distributable Earnings of $2.3 growing to a guided $6.95 by 2030 on the other, i.e. 20.2x today and 6.7x on 2030. Both point the same way, which is what supports "I want to make Brookfield Corporation (one of) the largest positions."
Watch for
- Both measures sharing an input — if the NAV and the earnings forecast both come from the same management model, they are not independent.
- The 2030 figure being a plan, not a fact; a 25% compound growth rate is a strong assumption to embed in an entry price.
8. Build an expected return from disclosed inputs instead of a target multiple
The repeatable method
- Start with the earnings yield (earnings ÷ price) rather than the P/E, so the number is already in units of return.
- Multiply it by the share of profits actually returned to shareholders in dividends and buybacks to get the cash-return leg.
- Add the organic revenue growth rate and the earnings growth rate the company has been delivering.
- Sum to a range, and present the inputs so any single one can be challenged without discarding the framework.
- Note what is deliberately excluded: no multiple re-rating. A return that needs the multiple to expand is a different, weaker claim.
Here: AMP — an 85% payout on a 10% earnings yield gives 8.5%/yr, plus 3-4% revenue growth and 6-7% earnings growth, "and you get an expected return of 14.5%-15.5%."
Watch for
- Buybacks executed above intrinsic value — the cash-return leg only counts fully if the shares retired were cheap.
- A fee-based earnings yield that is a cyclical peak; the whole sum rests on the E in the yield being durable.
9. Test pricing power with an actual annual number, not an adjective
The repeatable method
- Ask what the company raised prices by last year, and the year before, and whether volume grew anyway.
- A moat claim that cannot produce that pair of numbers is a story; one that can is measurable and repeatable.
- Then look for unpriced optionality attached to the same asset — licensing, adaptation rights, a partner distributing the IP — and treat it as upside rather than as part of the case.
Here: GAW.L — "Every year, they raise the price of their products by 4-5% and players just keep buying more," compounding to +14,300% since 1994; the Amazon Warhammer 40,000 film and TV rights are named separately as "optionality."
Watch for
- Price rises that start buying volume declines — the first year the pair breaks is the signal, not the price rise itself.
10. Anchor a demand thesis to a social trend rather than a product cycle
The repeatable method
- Ask what slow-moving change in how people live drives the spending, and whether it is reversible within your holding period.
- Prefer spending driven by emotion or obligation over discretionary spending — it survives a recession better.
- Then check the price separately; a good trend at a high multiple is still a bad entry.
Here: ZTS — "Loneliness is becoming a serious problem in our society… people are treating their pets as a full family member nowadays," paired with a 17.2x forward PE, "the cheapest valuation level of the past 10 years."
Watch for
- The trend being real but already fully priced, which is the usual failure mode of demographic theses.
11. Notice when the whole book goes cheap at once — and ask why
The repeatable method
- Track each holding's valuation against its own ten-year history, not against the market.
- When most of a portfolio simultaneously reaches decade-low multiples on unchanged fundamentals, the cause is almost certainly the discount rate or sentiment rather than the businesses.
- Separate the names where the fundamentals also weakened — those are not in the same category and should not be bought on the same reasoning.
- Use the observation to decide sizing (adding to the strongest convictions) rather than to add new names.
Here: the same phrase recurs across KNSL, V, CSU.TO, TOI.V, BRO and ZTS — cheapest in ten years, or ever — prompting the aside "do you start noticing a trend here?", alongside the intent to make BN one of the largest positions.
Watch for
- The possibility that the market is right about a common factor you own repeatedly — here, quality compounders re-rating together on AI and rate fears.
- Concentration creeping in through additions rather than through a decision.
Methods distilled from the archived Compounding Quality post for personal study. Not investment advice.